Europe has become one of the world’s leading hubs for biologics innovation, combining scientific excellence, regulatory expertise, and advanced manufacturing capabilities. As biologics become increasingly complex and development timelines continue to shorten, choosing the right CDMO has become a strategic decision that can significantly influence a program’s success.
In this article, we explore how the European CDMO model is evolving to meet these challenges, why integrated development and manufacturing services are becoming essential, and how early decisions around scalability, quality, and regulatory alignment shape the future of biologic therapies.
Download the full article to discover how 3PBIOVIAN’s pan-European infrastructure, broad technological expertise, and end-to-end development and manufacturing capabilities help biotech and pharmaceutical companies accelerate innovation while reducing complexity throughout the product lifecycle.